Molecule Explorer
Molecule Explorer
Molecule-level intelligence: innovator brand, patent status, US market size, dosage forms, generic competition, price erosion, complexity and Rubicon relevance.
Modeled estimates
What this shows
A reference library of individual drug molecules — the building blocks of the generics business. For each one: who invented it, when its patent lapses, how big the US market is, how many copycats exist and how much price has eroded.
How to use it
Scan the table; violet-tinted rows are molecules relevant to Rubicon. The right-most bar is Rubicon's fit score. Use this alongside the Product Opportunity Scanner, which turns these attributes into a ranked shortlist.
Key terms
- Innovator brand
- — The original branded drug the generic copies (e.g. Vyvanse, Narcan).
- Patent expiry
- — When the originator's patent protection ends and generics can legally launch.
- ANDA
- — US FDA generic-drug filing. The numbers show filings / approvals for that molecule.
- Dosage form
- — The physical format — tablet, capsule, spray, patch, injectable.
Molecule Database
10 molecules · regulated-market generic & complex-generic candidates
| Molecule | Innovator | Patent | US mkt | Dosage forms | ANDAs | Erosion | Pathway | API risk | Rubicon score |
|---|---|---|---|---|---|---|---|---|---|
| Lisdexamfetamine Dimesylate CNS / ADHD | Vyvanse | Expired (2023) | $3.1B | Capsule, Chewable | 14/9 | 55% | ANDA (Sch II) | Medium — controlled substance quota | 84 |
| Icosapent Ethyl Cardio-metabolic | Vascepa | Litigated / partial | $1.4B | Soft-gel capsule | 8/5 | 40% | ANDA (Para IV) | Medium — specialized lipid API | 78 |
| Tacrolimus Immunosuppressant | Astagraf XL / Envarsus | ER forms partly protected | $650M | IR capsule, ER tablet, ER capsule | 6/4 | 25% | ANDA (NTI) | Medium — HPAPI handling | 81 |
| Naloxone HCl Emergency / Opioid reversal | Narcan | Device IP active | $560M | Nasal spray, Injection | 6/3 | 30% | ANDA (device) | Low API; device critical | 76 |
| Dexmethylphenidate HCl CNS / ADHD | Focalin XR | Expired | $720M | ER capsule | 9/4 | 50% | ANDA (Sch II, ER) | Medium — quota | 80 |
| Budesonide Gastrointestinal / Respiratory | Entocort / Uceris | Expired | $380M | DR/ER capsule, Inhalation, Rectal foam | 10/5 | 45% | ANDA (complex) | Low | 74 |
| Liraglutide Diabetes / Obesity (GLP-1) | Victoza / Saxenda | Expiring | $2.6B | Pre-filled pen (injectable) | 4/1 | 20% | ANDA/505(b)(2) (device) | High — peptide + device | 62 |
| Fluticasone/Salmeterol Respiratory | Advair Diskus | Expired | $1.9B | Dry powder inhaler | 7/3 | 35% | ANDA (device, complex) | Medium — micronization + device | 58 |
| Rivastigmine CNS / Alzheimer's | Exelon Patch | Expired | $420M | Transdermal patch, Capsule | 6/4 | 40% | ANDA (transdermal) | Medium — adhesive/permeation | 70 |
| Paliperidone Palmitate CNS / Schizophrenia | Invega Sustenna | Active patents | $1.7B | Depot injection (LAI) | 3/0 | 5% | ANDA (depot, complex) | High — depot/long-acting | 66 |